Envista Holdings Receives 'Moderate Buy' Rating from Analysts

Sixteen brokerages cover the dental products company, with eight holding a 'hold' rating and seven issuing 'buy' recommendations.

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Envista Holdings Corporation (NYSE:NVST), a global dental products company, has received an average rating of "Moderate Buy" from the sixteen brokerages currently covering the firm, according to Marketbeat Ratings. The analysts' average 12-month price target for the stock is $27.0769.

Why it matters

Envista's product portfolio spans implant, orthodontic, endodontic, and restorative lines, as well as digital imaging systems and practice management software. The company's performance and analyst ratings provide insight into the state of the dental products industry and the market's outlook for Envista's business.

The details

The sixteen brokerages covering Envista have issued eight hold ratings, seven buy ratings, and one strong buy rating on the stock. Analysts have cited Envista's diverse product offerings and recent financial performance as factors contributing to the 'Moderate Buy' consensus rating.

  • Envista reported its latest quarterly earnings on February 5, 2026.

The players

Envista Holdings Corporation

A global dental products company that develops, manufactures, and markets a broad portfolio of dental consumables, equipment, and technology solutions.

Mizuho

An investment bank that has lifted its target price for Envista from $24.00 to $27.00 and maintained a 'neutral' rating on the stock.

William Blair

An investment bank that has upgraded Envista from a 'hold' rating to an 'outperform' rating.

Robert W. Baird

An investment bank that has set a $30.00 price target on Envista.

UBS Group

An investment bank that has increased its price target for Envista from $22.00 to $25.00 and maintained a 'neutral' rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

Envista's 'Moderate Buy' rating from analysts reflects the company's diverse product portfolio and recent financial performance, providing insight into the state of the dental products industry and the market's outlook for Envista's business.